Rise of Alnylam, ISIS Gives RNA Therapeutics Value
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
ISIS
Isis Pharmaceuticals to Present at the 2014 RBC Capital Markets Global Healthcare Conference
[PR Newswire] – CARLSBAD, Calif., Feb. 19, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 RBC Capital Markets Global Healthcare Con moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click […]
Positive Opinion on Isis Pharma’s ISIS-TTRRx
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
1:33 pm ISIS Pharm announces positive opinion on European Orphan Drug Designation for ISIS-TTR Rx
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
Isis Pharmaceuticals’ Spinal Muscular Atrophy Drug Advances in Phase 2 Trials
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
1:33 pm ISIS Pharm announces positive opinion on European Orphan Drug Designation for ISIS-TTR Rx
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
Isis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
[PR Newswire] – CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTRRx for designation as an orphan moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click […]
7:05 am ISIS Pharm announces that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN in children with spinal muscular atrophy; co will receive $9.3 mln in milestone payments
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
Isis Pharmaceuticals Advances ISIS-SMN Rx in Infants and Children with Spinal Muscular Atrophy
[PR Newswire] – CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atroph moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis […]
Health-care-related stocks keep on giving
moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]
